SG10202110737WA - Methods for detection of tau protein aggregation modulating compounds - Google Patents

Methods for detection of tau protein aggregation modulating compounds

Info

Publication number
SG10202110737WA
SG10202110737WA SG10202110737WA SG10202110737WA SG10202110737WA SG 10202110737W A SG10202110737W A SG 10202110737WA SG 10202110737W A SG10202110737W A SG 10202110737WA SG 10202110737W A SG10202110737W A SG 10202110737WA SG 10202110737W A SG10202110737W A SG 10202110737WA
Authority
SG
Singapore
Prior art keywords
detection
methods
tau protein
protein aggregation
modulating compounds
Prior art date
Application number
SG10202110737WA
Inventor
Rodriguez Rosa Crespo
Constantin Apetri
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG10202110737WA publication Critical patent/SG10202110737WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
SG10202110737WA 2017-03-28 2018-03-27 Methods for detection of tau protein aggregation modulating compounds SG10202110737WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17163426 2017-03-28

Publications (1)

Publication Number Publication Date
SG10202110737WA true SG10202110737WA (en) 2021-11-29

Family

ID=58464226

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202110737WA SG10202110737WA (en) 2017-03-28 2018-03-27 Methods for detection of tau protein aggregation modulating compounds
SG11201908085X SG11201908085XA (en) 2017-03-28 2018-03-27 Methods for detection of tau protein aggregation modulating compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201908085X SG11201908085XA (en) 2017-03-28 2018-03-27 Methods for detection of tau protein aggregation modulating compounds

Country Status (10)

Country Link
US (1) US11249093B2 (en)
EP (1) EP3602046A1 (en)
JP (1) JP2020515846A (en)
KR (1) KR20190127860A (en)
CN (1) CN110446925A (en)
AU (1) AU2018241860A1 (en)
CA (1) CA3055866A1 (en)
EA (1) EA201992280A1 (en)
SG (2) SG10202110737WA (en)
WO (1) WO2018178080A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47499A (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc ANTI-TAU BODIES AND THEIR METHODS OF USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610829D0 (en) * 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
AU5757598A (en) * 1996-12-13 1998-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
AU7653100A (en) * 1999-09-09 2001-04-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. A minimal tau peptide for the nucleation of paired helical filaments
US7172875B2 (en) * 2003-02-18 2007-02-06 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
US20070218491A1 (en) * 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
US9464122B2 (en) * 2008-08-20 2016-10-11 Oligomerix, Inc. Methods and compositions comprising tau oligomers
US20130295021A1 (en) * 2010-10-11 2013-11-07 Feng Chen Human anti-tau antibodies
US20130337463A1 (en) * 2010-11-05 2013-12-19 The Trustees Of The University Of Pennsylvania Cell-Based Models of Neurodegenerative Disease
US8865754B2 (en) * 2011-03-03 2014-10-21 Proteotech Inc. Compounds for the treatment of neurodegenerative diseases
MX2015008024A (en) * 2012-12-21 2016-08-08 Biogen Int Neuroscience Gmbh Human anti-tau antibodies.
WO2016123401A1 (en) * 2015-01-28 2016-08-04 University Of Delaware Detection of disease-associated tau protein conformations and applications thereof
US20190029977A1 (en) * 2017-04-24 2019-01-31 Mercaptor Discoveries, Inc. Use of Thiol Compounds to Treat Neurological Disease
EP3784687A1 (en) * 2018-04-27 2021-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) A method for preparing phfs-like tau aggregates

Also Published As

Publication number Publication date
EP3602046A1 (en) 2020-02-05
EA201992280A1 (en) 2020-02-13
KR20190127860A (en) 2019-11-13
US20200025777A1 (en) 2020-01-23
AU2018241860A1 (en) 2019-09-19
JP2020515846A (en) 2020-05-28
WO2018178080A1 (en) 2018-10-04
US11249093B2 (en) 2022-02-15
SG11201908085XA (en) 2019-10-30
CA3055866A1 (en) 2018-10-04
CN110446925A (en) 2019-11-12

Similar Documents

Publication Publication Date Title
HK1254357A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3218483A4 (en) Compounds and methods for the modulation of proteins
IL258528A (en) Modulation of gene expression and screening for deregulated protein expression
IL267559A (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3304431A4 (en) Open registry for identity of things
HRP20201107T8 (en) Heteroaryl amides as inhibitors of protein aggregation
HK1254289A1 (en) Methods and antibodies for modulation of immunoresponse
IL267993A (en) Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
IL267994A (en) Bis-heteroaryl derivatives as modulators of protein aggregation
EP3328379A4 (en) Bis-heteroaryl derivatives as modulators of protein aggregation
EP3142679A4 (en) Peptide inhibitors of bcr-abl oligomerization
GB2546719B (en) Modulation of gene expression and screening for deregulated protein expression
EP3313865A4 (en) Synthetic peptide compounds and methods of use
GB201803553D0 (en) Detection of pathological protein aggregation
IL268003A (en) Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
SG10202110737WA (en) Methods for detection of tau protein aggregation modulating compounds
GB201703033D0 (en) Detection of membrane proteins
EP3296314A4 (en) Protein aggregation inhibitor
GB201603507D0 (en) Detection of membrane proteins
EP3170901A4 (en) Method for identifying epitope of protein
GB201415425D0 (en) Small molecule inhibitors of classiv bromodomain proteins
GB201505911D0 (en) Small molecule inhibitors of class IV bromodomain proteins
AU2014902730A0 (en) Methods of inhibiting transmembrane proteins